- Home
- GGB vs AXSM Comparison
GGB vs AXSM Comparison
Compare GGB & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- AXSM
- Stock Information
- Founded
- GGB 1901
- AXSM 2012
- Country
- GGB Brazil
- AXSM United States
- Employees
- GGB N/A
- AXSM N/A
- Industry
- GGB Steel/Iron Ore
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- AXSM Health Care
- Exchange
- GGB Nasdaq
- AXSM Nasdaq
- Market Cap
- GGB 5.9B
- AXSM 6.3B
- IPO Year
- GGB 1999
- AXSM 2015
- Fundamental
- Price
- GGB $2.88
- AXSM $109.75
- Analyst Decision
- GGB Buy
- AXSM Strong Buy
- Analyst Count
- GGB 3
- AXSM 14
- Target Price
- GGB $5.00
- AXSM $168.93
- AVG Volume (30 Days)
- GGB 7.8M
- AXSM 623.1K
- Earning Date
- GGB 04-28-2025
- AXSM 05-05-2025
- Dividend Yield
- GGB 4.84%
- AXSM N/A
- EPS Growth
- GGB N/A
- AXSM N/A
- EPS
- GGB 0.35
- AXSM N/A
- Revenue
- GGB $10,837,144,685.00
- AXSM $385,693,000.00
- Revenue This Year
- GGB $8.01
- AXSM $64.53
- Revenue Next Year
- GGB $4.95
- AXSM $63.26
- P/E Ratio
- GGB $7.85
- AXSM N/A
- Revenue Growth
- GGB N/A
- AXSM 42.53
- 52 Week Low
- GGB $2.67
- AXSM $64.11
- 52 Week High
- GGB $4.04
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- GGB 45.15
- AXSM 34.08
- Support Level
- GGB $2.80
- AXSM $107.00
- Resistance Level
- GGB $2.96
- AXSM $122.97
- Average True Range (ATR)
- GGB 0.07
- AXSM 4.30
- MACD
- GGB -0.01
- AXSM -1.94
- Stochastic Oscillator
- GGB 26.79
- AXSM 11.85
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.